

COMPANY UPDATE – REPLACEMENT PROSPECTUS

Sydney, Australia 5 March 2021 – further to its announcement on 18 February 2021, the Board of Azure Health Technology Limited (**AZT** or the **Company**) is pleased to announce that it has now lodged a Replacement Prospectus in a form approved by ASIC (which includes certain changes to address various requisitions that ASIC had) and as a result, the Company will proceed with a Capital Raise via Public Offer of up to 15 million shares at a price of \$0.20 per share to raise up to \$3 million.

Indicative Timetable

An indicative timetable relating to the proposed Offer is set out below:

Particulars	Date
Replacement Prospectus lodgement	3 March 2021
Offer Period opens	5 March 2021
Offer Period closes	1 April 2021
Settlement of the Offer	13 April 2021
Issue of Shares	13 April 2021
Expected commencement of trading on NSX	16 April 2021
Expected dispatch of holding statements	16 April 2021

Please note this timetable is indicative only and the Directors reserve the right to amend the timetable as required.

Further details are provided in the Replacement Prospectus which can be found on the Company's website at: <https://events.miraqle.com/AZT-OFFER>

For more information please contact:

Dr Glenn Tong
CEO and Managing Director
Tel: +61 (0) 412 193 350

Catriona Glover
Company Secretary
Tel: +61 (0) 402 328 200

About Azure Health Technology Limited

Azure Health Technology Limited (AZT) is an Australian public unlisted biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. AZT owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

For more information see: <https://www.azureht.com.au>